The important role of routine cytopathology in pediatric precision oncology.

Humans Immunohistochemistry Medical Oncology Neoplasms / drug therapy Pathology Precision Medicine
cytopathology pediatrics precision oncology primary cell culture validation study

Journal

Cancer cytopathology
ISSN: 1934-6638
Titre abrégé: Cancer Cytopathol
Pays: United States
ID NLM: 101499453

Informations de publication

Date de publication:
10 2021
Historique:
revised: 14 04 2021
received: 15 03 2021
accepted: 16 04 2021
pubmed: 28 5 2021
medline: 12 2 2022
entrez: 27 5 2021
Statut: ppublish

Résumé

The development of high-throughput drug screening (HTS) using primary cultures provides a promising, clinically translatable approach to tailoring treatment strategies for patients with cancer. However, this has been challenging for solid tumors because of often limited amounts of tissue available. In most cases, in vitro expansion is required before HTS, which may lead to overgrowth and contamination by non-neoplastic cells. In this study, hematoxylin and eosin staining and immunohistochemical staining were performed on 129 cytopathology cases from 95 patients. These cytopathology cases comprised cell block preparations derived from primary tumor specimens or patient-derived xenografts as part of a pediatric precision oncology trial. Cytopathology cases were compared with the morphology and immunohistochemical staining profile of the original tumor. Cases were reported as tumor cells present, equivocal, or tumor cells absent. The HTS results from cytopathologically validated cultures were incorporated into a multidisciplinary tumor board report issued to the treating clinician to guide clinical decision making. On cytopathologic examination, tumor cells were present in 77 of 129 cases (60%) and were absent in 38 of 129 cases (29%), whereas 14 of 129 cases (11%) were equivocal. Cultures that contained tumor cells resembled the tumors from which they were derived. Cytopathologic examination of tumor cell block preparations is feasible and provides detailed morphologic characterization. Cytopathologic examination is essential for ensuring that samples submitted for HTS contain representative tumor cells and that in vitro drug sensitivity data are clinically translatable.

Sections du résumé

BACKGROUND
The development of high-throughput drug screening (HTS) using primary cultures provides a promising, clinically translatable approach to tailoring treatment strategies for patients with cancer. However, this has been challenging for solid tumors because of often limited amounts of tissue available. In most cases, in vitro expansion is required before HTS, which may lead to overgrowth and contamination by non-neoplastic cells.
METHODS
In this study, hematoxylin and eosin staining and immunohistochemical staining were performed on 129 cytopathology cases from 95 patients. These cytopathology cases comprised cell block preparations derived from primary tumor specimens or patient-derived xenografts as part of a pediatric precision oncology trial. Cytopathology cases were compared with the morphology and immunohistochemical staining profile of the original tumor. Cases were reported as tumor cells present, equivocal, or tumor cells absent. The HTS results from cytopathologically validated cultures were incorporated into a multidisciplinary tumor board report issued to the treating clinician to guide clinical decision making.
RESULTS
On cytopathologic examination, tumor cells were present in 77 of 129 cases (60%) and were absent in 38 of 129 cases (29%), whereas 14 of 129 cases (11%) were equivocal. Cultures that contained tumor cells resembled the tumors from which they were derived.
CONCLUSIONS
Cytopathologic examination of tumor cell block preparations is feasible and provides detailed morphologic characterization. Cytopathologic examination is essential for ensuring that samples submitted for HTS contain representative tumor cells and that in vitro drug sensitivity data are clinically translatable.

Identifiants

DOI: 10.1002/cncy.22448 PMID: 34043284
pubmed: 34043284
doi: 10.1002/cncy.22448
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

805-818

Subventions

Organisme : Cure Brain Cancer Foundation
Organisme : Cancer Therapeutics Cooperative Research Centre
Organisme : Robert Connor Dawes Foundation
Organisme : National Health and Medical Research Council of Australia
ID : APP1059804
Organisme : National Health and Medical Research Council of Australia
ID : APP1157871
Organisme : Australian Federal Government Department of Health funding

Informations de copyright

© 2021 American Cancer Society.

Références

Lawrence MS, Stojanov P, Mermel CH, et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature. 2014;505:495-501. doi:10.1038/nature12912
Lawrence MS, Stojanov P, Polak P, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013;499:214-218. doi:10.1038/nature12213
Zack TI, Schumacher SE, Carter SL, et al. Pan-cancer patterns of somatic copy number alteration. Nat Genet. 2013;45:1134-1140. doi:10.1038/ng.2760
Wong M, Mayoh C, Lau LMS, et al. Whole genome, transcriptome and methylome profiling enhances actionable target discovery in high-risk pediatric cancer. Nat Med. 2020;26:1742-1753. doi:10.1038/s41591-020-1072-4
The National Comprehensive Cancer Network Acute Myeloid Leukemia (AML) Treatment Regimens. Revised January 1, 2020. Accessed March 15, 2021. CancerTherapyAdvisor.com
Townsend E, Murakami M, Christodoulou A, et al. The public repository of xenografts enables discovery and randomized phase II-like trials in mice. Cancer Cell. 2016;30:183. doi:10.1016/j.ccell.2016.06.008
Kenny HA, Lal-Nag M, White EA, et al. Quantitative high throughput screening using a primary human three-dimensional organotypic culture predicts in vivo efficacy. Nat Commun. 2015;6:6220. doi:10.1038/ncomms7220
Skaga E, Kulesskiy E, Brynjulvsen M, et al. Feasibility study of using high-throughput drug sensitivity testing to target recurrent glioblastoma stem cells for individualized treatment. Clin Transl Med. 2019;8:33. doi:10.1186/s40169-019-0253-6
Ibarrola-Villava M, Cervantes A, Bardelli A. Preclinical models for precision oncology. Biochim Biophys Acta Rev Cancer. 2018;1870:239-246. doi:10.1016/j.bbcan.2018.06.004
Hamacher R, Bauer S. Preclinical models for translational sarcoma research. Curr Opin Oncol. 2017;29:275-285. doi:10.1097/CCO.0000000000000373
Schütte M, Risch T, Abdavi-Azar N, et al. Molecular dissection of colorectal cancer in pre-clinical models identifies biomarkers predicting sensitivity to EGFR inhibitors. Nat Commun. 2017;8:14262. doi:10.1038/ncomms14262
Pauli C, Hopkins BD, Prandi D, et al. Personalized in vitro and in vivo cancer models to guide precision medicine. Cancer Discov. 2017;7:462-477. doi:10.1158/2159-8290.CD-16-1154
Lohse I, Statz-Geary K, Brothers SP, Wahlestedt C. Precision medicine in the treatment stratification of AML patients: challenges and progress. Oncotarget. 2018;9:37790-37797. doi:10.18632/oncotarget.26492
Jabs J, Zickgraf FM, Park J, et al. Screening drug effects in patient-derived cancer cells links organoid responses to genome alterations. Mol Syst Biol. 2017;13:955. doi:10.15252/msb.20177697
Salawu A, Fernando M, Hughes D, et al. Establishment and molecular characterisation of seven novel soft-tissue sarcoma cell lines. Br J Cancer. 2016;115:1058-1068. doi:10.1038/bjc.2016.259
Volchenboum SL, Li C, Li S, et al. Comparison of primary neuroblastoma tumors and derivative early passage cell lines using genome-wide single nucleotide polymorphism array analysis. Cancer Res. 2009;69:4143-4149. doi:10.1158/0008-5472.CAN-08-3112
van de Wetering M, Francies H, Francis J, et al. Prospective derivation of a living organoid biobank of colorectal cancer patients. Cell. 2015;161:933-945. doi:10.1016/j.cell.2015.03.053
Betz BL, Dixon CA, Weigelin HC, Knoepp SM, Roh MH. The use of stained cytologic direct smears for ALK gene rearrangement analysis of lung adenocarcinoma. Cancer Cytopathol. 2013;121:489-499. doi:10.1002/cncy.21286
Tsai S, McOlash L, Palen K, et al. Development of primary human pancreatic cancer organoids, matched stromal and immune cells and 3D tumor microenvironment models. BMC Cancer. 2018;18:335. doi:10.1186/s12885-018-4238-4
Ehlen L, Arndt J, Treue D, et al. Novel methods for in vitro modeling of pancreatic cancer reveal important aspects for successful primary cell culture. BMC Cancer. 2020;20:417. doi:10.1186/s12885-020-06929-8
Lin M, Gao M, Cavnar MJ, Kim J. Utilizing gastric cancer organoids to assess tumor biology and personalize medicine. World J Gastrointest Oncol. 2019;11:509-517. doi:10.4251/wjgo.v11.i7.509
Barton J, Pacey K, Jain N, et al. Establishment and phenotyping of neurosphere cultures from primary neuroblastoma samples. F1000Res. 2019;8:823. doi:10.12688/f1000research.18209.1
Yanagisawa M, Yoshimura S, Yu RK. Expression of GD2 and GD3 gangliosides in human embryonic neural stem cells. ASN Neuro. 2011;3:e00054. doi:10.1042/AN20110006
Poli A, Michel T, Theresine M, Andres E, Hentges F, Zimmer J. CD56bright natural killer (NK) cells: an important NK cell subset. Immunology. 2009;126:458-465. doi:10.1111/j.1365-2567.2008.03027.x
Kamili A, Gifford AJ, Li N, et al. Accelerating development of high-risk neuroblastoma patient-derived xenograft models for pre-clinical testing and personalised therapy. Br J Cancer. 2020;122:680-691. doi:10.1038/s41416-019-0682-4
Lin GL, Monje M. A protocol for rapid post-mortem cell culture of diffuse intrinsic pontine glioma (DIPG). J Vis Exp. 2017;121:55360. doi:10.3791/55360
Shen H, Tang Y, Dong A, et al. Staging and monitoring of childhood rhabdomyosarcoma with flow cytometry. Oncol Lett. 2014;7:970-976. doi:10.3892/ol.2014.1854
Pinto A, Dickman P, Parham D. Pathobiologic markers of the Ewing sarcoma family of tumors: state of the art and prediction of behaviour. Sarcoma. 2011;2011:856190. doi:10.1155/2011/856190
Mujoo K, Cheresh DA, Yang HM, Reisfeld RA. Disialoganglioside GD2 on human neuroblastoma cells: target antigen for monoclonal antibody-mediated cytolysis and suppression of tumor growth. Cancer Res. 1987;47:1098-1104.
Li B, McCrudden CM, Yuen HF, et al. CD133 in brain tumor: the prognostic factor. Oncotarget. 2017;8:11144-11159. doi:10.18632/oncotarget.14406
He J, Liu Y, Zhu T, et al. CD90 is identified as a candidate marker for cancer stem cells in primary high-grade gliomas using tissue microarrays. Mol Cell Proteomics. 2012;11:M111.010744. doi:10.1074/mcp.M111.010744
Trevethan R. Sensitivity, specificity, and predictive values: foundations, pliabilities, and pitfalls in research and practice. Front Public Health. 2017;5:307. doi:10.3389/fpubh.2017.00307
Pavon LF, Sibov TT, Caminada de Toledo SR, et al. Establishment of primary cell culture and an intracranial xenograft model of pediatric ependymoma: a prospect for therapy development and understanding of tumor biology. Oncotarget. 2018;9:21731-21743. doi:10.18632/oncotarget.24932
Bate-Eya LT, Ebus ME, Koster J, et al. Newly-derived neuroblastoma cell lines propagated in serum-free media recapitulate the genotype and phenotype of primary neuroblastoma tumours. Eur J Cancer. 2014;50:628-637. doi:10.1016/j.ejca.2013.11.015
Gröbner SN, Worst BC, Weischenfeldt J, et al. The landscape of genomic alterations across childhood cancers. Nature. 2018;555:321-327. doi:10.1038/nature25480
Fong ELS, Toh TB, Yu H, Chow EK. 3D culture as a clinically relevant model for personalized medicine. SLAS Technol. 2017;22:245-253. doi:10.1177/2472630317697251
Gieniec KA, Butler LM, Worthley DL, Woods SL. Cancer-associated fibroblasts-heroes or villains? Br J Cancer. 2019;121:293-302. doi:10.1038/s41416-019-0509-3
Matias-Guiu X, Stanta G, Carneiro F, et al. The leading role of pathology in assessing the somatic molecular alterations of cancer: position paper of the European Society of Pathology. Virchows Arch. 2020;476:491-497. doi:10.1007/s00428-020-02757-0
Pauli C, Puca L, Mosquera JM, et al. An emerging role for cytopathology in precision oncology. Cancer Cytopathol. 2016;124:167-173. doi:10.1002/cncy.21647
Sailer V, Pauli C, Merzier EC, et al. On-site cytology for development of patient-derived three-dimensional organoid cultures-a pilot study. Anticancer Res. 2017;37:1569-1573. doi:10.21873/anticanres.11486
Kodack DP, Farago AF, Dastur A, et al. Primary patient-derived cancer cells and their potential for personalized cancer patient care. Cell Rep. 2017;21:3298-3309. doi:10.1016/j.celrep.2017.11.051
Bartlett R, Everett W, Lim S, et al. Personalized in vitro cancer modeling-fantasy or reality? Transl Oncol. 2014;7:657-664. doi:10.1016/j.tranon.2014.10.006

Auteurs

Jinhan Xie (J)

Children's Cancer Institute, Lowy Cancer Research Centre, University of New South Wales (UNSW) Sydney, Randwick, New South Wales, Australia.
School of Women's and Children's Health, UNSW Sydney, Randwick, New South Wales, Australia.
ORCID: 0000-0001-8771-9533

Amit Kumar (A)

Children's Cancer Institute, Lowy Cancer Research Centre, University of New South Wales (UNSW) Sydney, Randwick, New South Wales, Australia.
Peter MacCallum Cancer Center, Melbourne, Victoria, Australia.

M Emmy M Dolman (MEM)

Children's Cancer Institute, Lowy Cancer Research Centre, University of New South Wales (UNSW) Sydney, Randwick, New South Wales, Australia.

Chelsea Mayoh (C)

Children's Cancer Institute, Lowy Cancer Research Centre, University of New South Wales (UNSW) Sydney, Randwick, New South Wales, Australia.
School of Women's and Children's Health, UNSW Sydney, Randwick, New South Wales, Australia.

Dong-Anh Khuong-Quang (DA)

Children's Cancer Center, Murdoch Children's Research Institute, The Royal Children's Hospital, Melbourne, Victoria, Australia.

Roxanne Cadiz (R)

Children's Cancer Institute, Lowy Cancer Research Centre, University of New South Wales (UNSW) Sydney, Randwick, New South Wales, Australia.

Marie Wong-Erasmus (M)

Children's Cancer Institute, Lowy Cancer Research Centre, University of New South Wales (UNSW) Sydney, Randwick, New South Wales, Australia.

Emily V A Mould (EVA)

Children's Cancer Institute, Lowy Cancer Research Centre, University of New South Wales (UNSW) Sydney, Randwick, New South Wales, Australia.

Dylan Grebert-Wade (D)

Children's Cancer Institute, Lowy Cancer Research Centre, University of New South Wales (UNSW) Sydney, Randwick, New South Wales, Australia.

Paulette Barahona (P)

Children's Cancer Institute, Lowy Cancer Research Centre, University of New South Wales (UNSW) Sydney, Randwick, New South Wales, Australia.

Alvin Kamili (A)

Children's Cancer Institute, Lowy Cancer Research Centre, University of New South Wales (UNSW) Sydney, Randwick, New South Wales, Australia.
School of Women's and Children's Health, UNSW Sydney, Randwick, New South Wales, Australia.

Maria Tsoli (M)

Children's Cancer Institute, Lowy Cancer Research Centre, University of New South Wales (UNSW) Sydney, Randwick, New South Wales, Australia.

Timothy W Failes (TW)

Children's Cancer Institute, Lowy Cancer Research Centre, University of New South Wales (UNSW) Sydney, Randwick, New South Wales, Australia.
Australian Cancer Research Foundation Drug Discovery Center, Children's Cancer Institute, Lowy Cancer Research Centre, UNSW Sydney, Randwick, New South Wales, Australia.

Shu-Oi Chow (SO)

Children's Cancer Institute, Lowy Cancer Research Centre, University of New South Wales (UNSW) Sydney, Randwick, New South Wales, Australia.
Australian Cancer Research Foundation Drug Discovery Center, Children's Cancer Institute, Lowy Cancer Research Centre, UNSW Sydney, Randwick, New South Wales, Australia.

Greg M Arndt (GM)

Children's Cancer Institute, Lowy Cancer Research Centre, University of New South Wales (UNSW) Sydney, Randwick, New South Wales, Australia.
Australian Cancer Research Foundation Drug Discovery Center, Children's Cancer Institute, Lowy Cancer Research Centre, UNSW Sydney, Randwick, New South Wales, Australia.

Kanika Bhatia (K)

Children's Cancer Center, Murdoch Children's Research Institute, The Royal Children's Hospital, Melbourne, Victoria, Australia.

Glenn M Marshall (GM)

Children's Cancer Institute, Lowy Cancer Research Centre, University of New South Wales (UNSW) Sydney, Randwick, New South Wales, Australia.
Kids Cancer Center, Sydney Children's Hospital, Randwick, New South Wales, Australia.

David S Ziegler (DS)

Children's Cancer Institute, Lowy Cancer Research Centre, University of New South Wales (UNSW) Sydney, Randwick, New South Wales, Australia.
School of Women's and Children's Health, UNSW Sydney, Randwick, New South Wales, Australia.
Kids Cancer Center, Sydney Children's Hospital, Randwick, New South Wales, Australia.

Michelle Haber (M)

Children's Cancer Institute, Lowy Cancer Research Centre, University of New South Wales (UNSW) Sydney, Randwick, New South Wales, Australia.
School of Women's and Children's Health, UNSW Sydney, Randwick, New South Wales, Australia.

Richard B Lock (RB)

Children's Cancer Institute, Lowy Cancer Research Centre, University of New South Wales (UNSW) Sydney, Randwick, New South Wales, Australia.
School of Women's and Children's Health, UNSW Sydney, Randwick, New South Wales, Australia.

Vanessa Tyrrell (V)

Children's Cancer Institute, Lowy Cancer Research Centre, University of New South Wales (UNSW) Sydney, Randwick, New South Wales, Australia.

Loretta Lau (L)

Children's Cancer Institute, Lowy Cancer Research Centre, University of New South Wales (UNSW) Sydney, Randwick, New South Wales, Australia.
Children's Cancer Center, Royal Children's Hospital, Parkville, Victoria, Australia.

Penny Athanasatos (P)

Department of Anatomical Pathology, Prince of Wales Hospital, Randwick, New South Wales, Australia.

Andrew J Gifford (AJ)

Children's Cancer Institute, Lowy Cancer Research Centre, University of New South Wales (UNSW) Sydney, Randwick, New South Wales, Australia.
School of Women's and Children's Health, UNSW Sydney, Randwick, New South Wales, Australia.
Department of Anatomical Pathology, Prince of Wales Hospital, Randwick, New South Wales, Australia.
ORCID: 0000-0002-4092-2347

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › The important role of routine cytopathology in...
questionsmedicales.fr › Disciplines des sciences naturelles › Chimie › Biochimie › Immunohistochimie › The important role of routine cytopathology in...
questionsmedicales.fr › Professions de santé › Médecine › Médecine interne › Oncologie médicale › The important role of routine cytopathology in...
questionsmedicales.fr › Tumeurs › The important role of routine cytopathology in...
questionsmedicales.fr › Professions de santé › Médecine › Anatomopathologie › The important role of routine cytopathology in...
questionsmedicales.fr › Professions de santé › Médecine › Médecine clinique › Médecine de précision › The important role of routine cytopathology in...